With the number of people affected by the coronavirus approaching one million, the rapid spread of this virus is causing significant challenges to operating clinical trials—and may forever change how future clinical trials are conducted. Clinics and hospitals are less accessible, and it’s often unsafe or too difficult for patients enrolled in clinical trials to travel to sites.
Finding alternative site solutions and utilizing more innovative approaches are critical to keeping trials moving forward to prevent delays in therapies and, ultimately, to the patients who can benefit from them. The FDA and the National Institutes of Health, the EMA, and many more countries have issued guidelines pertaining to the conduct of trials during the pandemic, and are in full support of incorporating virtual services, where one or all patient visits do not happen in a clinic or hospital, but rather at home.
Learn how you can respond to the needs of your clients utilizing Direct to/from Patient and Home Healthcare services based on their needs and the requirements of each country.
Kimberly Finn, Vice President, Global Patient Centric Services, Marken
Kimberly Finn has extensive experience in the clinical trial industry having started her career as a CRA. Over the past 24 years she assumed roles of increasing responsibility within clinical operations and global project management in both pharma and CRO organizations. Finn’s expertise in protocol design and clinical strategy has contributed to successful on-time delivery of complex portfolios valued at greater than $300 million USD and she has directly contributed to the development of six New Drug Application (NDA)-approved and marketed compounds.Message Presenter
Sandra Voss, Director, Project Management Europe, Marken
Sandra Voss previously served as Marken’s Project Manager, Clinical Trial Logistics. During her time at Marken, Voss has managed multiple global projects in Clinical Trial Distribution and supported several additional functions within Marken such as Business Development, Pricing and Quality Assurance. Voss has taken a critical role in Marken’s Direct to Patient Services by developing related Standard Operating Procedures, training and certifying the Marken network as well as managing innovative projects in that area. Voss holds a Bachelor of Arts in International Management and obtained her Master degree in Sales and Marketing at University of Applied Sciences, RheinMain.Message Presenter
Who Should Attend?
This webinar will pertain to decision makers in:
- Central Labs
What You Will Learn
Attendees will learn about:
- Alternative site solutions to keeping trials moving forward during the COVID-19 pandemic
- Innovative approaches to prevent delays in therapies for patients who benefit from them
- Incorporating virtual services into your protocols
- Utilizing Direct to/from Patient and Home Healthcare services based on the needs of each country
Marken is a wholly owned subsidiary of the UPS Healthcare Division. With Polar Speed and Marken included, the UPS division staffs 128 locations with 5000 employees worldwide. Marken maintains the leading position for Direct to Patient and Home Health care services, biological sample shipments and offers a state-of-the-art GMP-compliant depot network and logistics hubs in 54 locations worldwide for clinical trial material storage and distribution. Marken’s dedicated 1200 staff members manage 90,000 drug and biological shipment every month at all temperature ranges in more than 220 countries Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy as to Marken’ unique position in the pharma and logistics industry.